Literature DB >> 11923872

Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization.

Muyang Li1, Delin Chen, Ariel Shiloh, Jianyuan Luo, Anatoly Y Nikolaev, Jun Qin, Wei Gu.   

Abstract

The p53 tumour suppressor is a short-lived protein that is maintained at low levels in normal cells by Mdm2-mediated ubiquitination and subsequent proteolysis. Stabilization of p53 is crucial for its tumour suppressor function. However, the precise mechanism by which ubiquitinated p53 levels are regulated in vivo is not completely understood. By mass spectrometry of affinity-purified p53-associated factors, we have identified herpesvirus-associated ubiquitin-specific protease (HAUSP) as a novel p53-interacting protein. HAUSP strongly stabilizes p53 even in the presence of excess Mdm2, and also induces p53-dependent cell growth repression and apoptosis. Significantly, HAUSP has an intrinsic enzymatic activity that specifically deubiquitinates p53 both in vitro and in vivo. In contrast, expression of a catalytically inactive point mutant of HAUSP in cells increases the levels of p53 ubiquitination and destabilizes p53. These findings reveal an important mechanism by which p53 can be stabilized by direct deubiquitination and also imply that HAUSP might function as a tumour suppressor in vivo through the stabilization of p53.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11923872     DOI: 10.1038/nature737

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  388 in total

1.  Otubains: a new family of cysteine proteases in the ubiquitin pathway.

Authors:  Maxim Y Balakirev; Sergey O Tcherniuk; Michel Jaquinod; Jadwiga Chroboczek
Journal:  EMBO Rep       Date:  2003-05       Impact factor: 8.807

Review 2.  USP7: Structure, substrate specificity, and inhibition.

Authors:  Alexandra Pozhidaeva; Irina Bezsonova
Journal:  DNA Repair (Amst)       Date:  2019-02-16

Review 3.  Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development.

Authors:  W-L Yang; X Zhang; H-K Lin
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

4.  Proteomic profiling of the human cytomegalovirus UL35 gene products reveals a role for UL35 in the DNA repair response.

Authors:  Jayme Salsman; Madhav Jagannathan; Patrick Paladino; Pak-Kei Chan; Graham Dellaire; Brian Raught; Lori Frappier
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

5.  Enzymatic assays for assessing histone deubiquitylation activity.

Authors:  Robyn T Sussman; Xiao-Yong Zhang; Steven B McMahon
Journal:  Methods       Date:  2011-04-12       Impact factor: 3.608

6.  Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB.

Authors:  Hasem Habelhah; Shoichi Takahashi; Ssang-Goo Cho; Takayuki Kadoya; Toshiki Watanabe; Ze'ev Ronai
Journal:  EMBO J       Date:  2004-01-08       Impact factor: 11.598

7.  Replication-initiator protein (UL9) of the herpes simplex virus 1 binds NFB42 and is degraded via the ubiquitin-proteasome pathway.

Authors:  Chi-Yong Eom; I Robert Lehman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-06       Impact factor: 11.205

8.  SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization.

Authors:  Ping Yi; Weiya Xia; Ray-Chang Wu; David M Lonard; Mien-Chie Hung; Bert W O'Malley
Journal:  Genes Dev       Date:  2013-02-01       Impact factor: 11.361

9.  Supervillin-mediated suppression of p53 protein enhances cell survival.

Authors:  Zhiyou Fang; Elizabeth J Luna
Journal:  J Biol Chem       Date:  2013-02-04       Impact factor: 5.157

10.  Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.

Authors:  Noa Rivlin; Shir Katz; Maayan Doody; Michal Sheffer; Stav Horesh; Alina Molchadsky; Gabriela Koifman; Yoav Shetzer; Naomi Goldfinger; Varda Rotter; Tamar Geiger
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.